Get the Stockscreener App
0.6016
6.12%
0.0347
After Hours:
.57
-0.0316
-5.25%
Moleculin Biotech Inc stock is traded at $0.6016, with a volume of 2.56M.
It is up +6.12% in the last 24 hours and down -1.54% over the past month.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
See More
Previous Close:
$0.5669
Open:
$0.551
24h Volume:
2.56M
Relative Volume:
1.98
Market Cap:
$12.26M
Revenue:
-
Net Income/Loss:
$-30.33M
P/E Ratio:
-0.0215
EPS:
-28.0369
Net Cash Flow:
$-24.28M
1W Performance:
-22.18%
1M Performance:
-1.54%
6M Performance:
-75.84%
1Y Performance:
-94.53%
1-Day Range:
$0.53
$0.6694
1-Week Range:
$0.50
$0.733
52-Week Range:
$0.1614
$15.75
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713-300-5160
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.6016 | 12.26M | 0 | -30.33M | -24.28M | -28.04 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Resumed | H.C. Wainwright | Buy |
| Feb-12-25 | Downgrade | Maxim Group | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
Form 8K Moleculin Biotech Inc For: 25 September By Investing.com - Investing.com Nigeria
Moleculin presents preclinical pancreatic cancer data at AACR - Investing.com
Annamycin Turns 'Cold” Pancreatic Tumors 'Hot” in New Preclinical Data Presented at AACR - manilatimes.net
Form 8-K Moleculin Biotech, Inc. For: Sep 25 - StreetInsider
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR - GlobeNewswire
Moleculin Biotech, Inc. (MBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Moleculin Biotech (NASDAQ: MBRX) Obtains Mexican Patent No. 436849 and Issues 888,400 Shares via ATM Offering - Kalkine Media
Moleculin Biotech Announces Mexican Patent Approval and ATM Share Offering Completion - Kalkine Media
Moleculin receives Mexican patent for Annamycin formulation By Investing.com - Investing.com Nigeria
Moleculin Biotech (MBRX) Strengthens IP with Mexican Patent Amid Challenging Valuation - GuruFocus
Moleculin Series I Warrant Exercise Price Cut to $0.51 After ATM Sales - Minichart
Form 8K Moleculin Biotech Inc For: 23 September By Investing.com - Investing.com Canada
Moleculin Secures Mexican Patent Strengthening Annamycin IP Portfolio - TipRanks
Moleculin receives Mexican patent for Annamycin formulation - Investing.com
Form 8K Moleculin Biotech Inc For: 23 September - Investing.com India
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 - GlobeNewswire
Moleculin Biotech stock falls 32.71 percent on September 21 - AD HOC NEWS
Form 8K Moleculin Biotech Inc For: 18 September By Investing.com - Investing.com Nigeria
Moleculin Biotech Stock Price Forecast. Should You Buy MBRX? - StockInvest.us
Moleculin Biotech receives Nasdaq delisting notice after minimum bid price violation - Investing.com
Moleculin Biotech Faces Nasdaq Delisting Risk After Notice - TipRanks
Moleculin Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Moleculin Showcases New Annamycin Data at September Conferences - TipRanks
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings - marketscreener.com
Moleculin to Showcase New Annamycin Data at AACR Conference - GlobeNewswire
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand - marketscreener.com
Moleculin Biotech at H.C. Wainwright conference: aml hope builds By Investing.com - Investing.com Australia
MBRX: Annamycin's phase III AML trial shows 3x higher remission rates and zero cardiotoxicity - TradingView
Moleculin Biotech at H.C. Wainwright conference: aml hope builds - Investing.com
MBRX: Annamycin's Phase III AML trial shows triple the remission rate of control with zero cardiotoxicity - TradingView
A biotech’s clinical update goes online before New York investor meetings - Stock Titan
Moleculin Biotech (MBRX) Holds Above $0.77 as Biotech Sector Watches Key Resistance at $0.81Trend Following Picks - siam.in
MBRX Should I Buy - Intellectia AI
Why Did MBRX Stock Climb 14% Today? - Stocktwits
Moleculin Biotech Inc. (MBRX) Peer Comparison – Compare with Others - Value Research
Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team - ACCESS Newswire
Moleculin Biotech Updates Investors with New Presentation - TipRanks
Moleculin (NASDAQ: MBRX) posts investor presentation online - Stock Titan
Moleculin Biotech Inc. (MBRX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
MBRX Q2 2026 Earnings: Loss Narrows More Than Expected, but Shares Slip 5.6%Guidance Update - careplusvn.com
MOLECULIN BIOTECH, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $3 FROM $22 - webull.com
Moleculin Biotech Inc. (MBRX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Moleculin Biotech Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Enterprise value to revenue forward of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor 'Why Now” On-Demand Conference - manilatimes.net
Signal Proxy Intelligence Recommends AGAINST Moleculin Biotech, Inc. Executive Compensation Ahead of Oct. 9, 2026 Annual Meeting (NASDAQ:MBRX) - kitv.com
Moleculin (MBRX) CFO put $220K into stock—how big a stake did he build? - Stock Titan
Should I buy Moleculin Biotech (MBRX) - Zacks Investment Research
Moleculin (MBRX) Chart: Rises 0.41% to $0.59 for the Current Session; Price Levels: the Supplied Trading Band Runs From $0.56 to $0.62 in the Latest SessionBPI Bear Confirmed - vinanet.vn
Moleculin (MBRX) Session: Finishes 0.08% Lower at $0.59 in Latest Trading; Level Watch: $0.56 and $0.62 Define the Nearby Reference Levels in the Current UpdateVolatility Skew - dars.gov.et
Moleculin Biotech Inc (NASDAQ: MBRX) Share Price, MBRX Stock News, MBRX Share Price & Updates - kalkine.ca
Moleculin Biotech Inc Stock (MBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):